Octreotide (Sandostatin Lar, Sandostatin) shortage status
Partial shortage
Source: Health Canada shortage reports · Updated Jul 22, 2026
Also sold as: Sandostatin Lar, Sandostatin, Ocphyl
Some Octreotide products are in shortage in Canada (3 of 14 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Nov 30, 2026.
A hormone-blocking medication used to treat acromegaly and symptoms caused by certain hormone-producing tumours.
Products affected
3 / 14
In shortage since
Jun 17, 2024
Est. full return
Nov 30, 2026
Reports on file
46
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
OCTREOTIDE ACETATE OMEGA
500MCG · SOLUTION · OMEGA LABORATORIES LIMITED
DIN 02248641 · since Jul 20, 2026, est. end Nov 30, 2026 · Disruption of the manufacture of the drug.
Active shortage
OCTREOTIDE ACETATE OMEGA
100MCG · SOLUTION · OMEGA LABORATORIES LIMITED
DIN 02248640 · since Jul 20, 2026, est. end Nov 30, 2026 · Disruption of the manufacture of the drug.
DIN 02503751 · ended May 5, 2026 · Disruption of the manufacture of the drug.
Showing 12 of 46 reports. All reports are on file with Health Canada.
What's happening
Octreotide is currently affected by 3 active shortage reports filed with Health Canada by OMEGA LABORATORIES LIMITED, NOVARTIS PHARMACEUTICALS CANADA INC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Octreotide is classified under “HYPOTHALAMIC HORMONES” (ATC H01CB).
Recent changes
Jul 22, 2026
New report filed
Jul 22, 2026
New report filed
Common questions
What is Octreotide used for?
A hormone-blocking medication used to treat acromegaly and symptoms caused by certain hormone-producing tumours.
When will Octreotide be back in stock in Canada?
The latest manufacturer estimate is Nov 30, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Octreotide in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.